A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)

This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
In Phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180 participants.
In the event that the stage gate for Phase 2B is reached, then Phase 2B will assesses efficacy and longer-term safety in a larger study group, i.e., 414.

开始日期2021-11-15

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02389413

/ Completed临床2期

A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease

The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.

开始日期2015-03-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

NCT02190708

/ Completed临床1期

A Phase I, Open Label Study to Assess the Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole in Healthy Male Subjects

Midazolam is a rapid-acting benzodiazepine, with a short half-life (approximately 1.9 hours) and is primarily metabolised by CYP3A.
Omeprazole is a selective proton pump inhibitor substrate used to reduce gastric acid secretion. Omeprazole is primarily metabolised by CYP2C19.
Midazolam and omeprazole are both used as probe drugs in clinical pharmacology studies to evaluate clinical CYP3A and CYP2C19 drug interactions, respectively. Furthermore the EMA and the FDA guidance on drug interactions recommend the use of these drugs for such evaluations.
The aim of this study is to assess the effect of PQ912 on the PK of midazolam and omeprazole. In vitro studies have demonstrated that PQ912 inhibits several CYP enzymes, including CYP3A4 and CYP2C19 and at the expected exposure levels in patients, has the potential to inhibit these enzymes in-vivo. This study is therefore planned to investigate the potential changes in the PK of midazolam and omeprazole due to the effect of PQ912 at steady-state. In clinical practice it is likely that co-administration of PQ912 with other drugs that are metabolised via the CYP3A and/or CYP2C19 enzymes will occur. This study will provide important information for the requirement of dose adjustments or contraindications in these circumstances.

开始日期2014-06-01

申办/合作机构

Vivoryon Therapeutics NV

[+1]

100 项与 Varoglutamstat 相关的临床结果

登录后查看更多信息

100 项与 Varoglutamstat 相关的转化医学

登录后查看更多信息

100 项与 Varoglutamstat 相关的专利（医药）

登录后查看更多信息

项与 Varoglutamstat 相关的文献（医药）

2026-05-01·JPAD-Journal of Prevention of Alzheimers Disease

Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial

Article

作者: Wassmann, Tanja ; Meyer, Antje ; MacKelfresh, Andrew J ; Schaeffer, Michael ; Duehring, Jasmin A ; Wenzkowski, Christine ; Jacobs, Diane M ; Revta, Carolyn ; Schell-Mader, Sylvia ; Edland, Steven D ; Feldman, Howard H ; Salmon, David P

BACKGROUND:

Cognitive-functional composite measures are increasingly used as primary efficacy endpoints in early Alzheimer's disease (AD) trials, where greater sensitivity to decline can improve trial efficiency and reduce sample size requirements.

OBJECTIVES:

To compare sensitivity to decline of the Cognitive Functional Component 2 (CFC2), a novel cognitive-functional composite measure described by Raghavan et al. (2013), against the Clinical Dementia Rating - Sum of Boxes (CDR-SB) and other standard cognitive and functional outcomes including MMSE, FAQ, ADAS Cog 13 and ADCOMS using prospective randomized clinical trial data.

DESIGN:

The VIVA-MIND trial was a phase 2A/2B randomized controlled trial investigating the safety and efficacy of varoglutamstat in patients with mild cognitive impairment and mild dementia due to AD.

SETTING:

The VIVA-MIND trial was conducted between 2021-2024. It was prematurely terminated in mid-2024 by the study sponsor.

PARTICIPANTS:

This secondary analysis uses data from 98 participants in the modified intention-to-treat population from the VIVA-MIND trial with complete neuropsychological test data.

MEASUREMENTS:

Standard power calculations informed by parameters estimated from linear mixed-effects models were used to determine the relative efficiency of outcome measures.

RESULTS:

The CFC2 was more sensitive to decline than the CDR-SB in this population. Use of the CFC2 would yield a 15% reduction in required sample size relative to the CDR-SB. Application of an optimal weighting scheme further improved the sensitivity of the CFC2.

CONCLUSIONS:

Practically significant differences in the efficiency of clinical trials in early AD may be realized by the choice of clinical outcome measure and weighting scheme. Although further verification is needed, we replicate a previous finding that the CFC2 may outperform the CDR-SB in the early AD population.

2025-12-01·Alzheimers & Dementia

Generalizability of digital speech and language assessments in MCI/mild AD across four non‐English languages

Article

作者: Schaeffer, Michael ; Xu, Mengdan ; Cormack, Francesca K ; Wenzkowski, Christine ; Lillo, Martina De ; Fuchs, Katharina ; Spilka, Michael J. ; Robin, Jessica

Abstract:

Background:

Neurodegenerative diseases affect speech production. Previous studies show various acoustic and linguistic changes in Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD) speech patterns, such as more pauses and lower usage of nouns. However, most research has focused on English speakers. This analysis examines speech features in MCI and AD patients across four languages to determine if digital speech assessments yield comparable results across different languages.

Method:

This study included 244 patients with MCI or mild AD enrolled in the Phase 2b VIVIAD trial of varoglutamstat, in four language groups: Danish ( n =84), German ( n =59), Dutch ( n =40), and Spanish ( n =61). A picture description task was administered to all patients at baseline using instructions in their respective languages. Five speech features including number of picture objects described, number of nouns, speech rate, pronoun‐to‐noun ratio and average of word length were chosen based on previous analyses of speech patterns in MCI/AD, and a composite score was calculated combining the five measures. We tested the interrelationships among the features in each language and examined whether the speech features were related to another measure of cognitive function, the Mini‐Mental State Exam (MMSE). Associations were examined using a correlational approach.

Result:

There was variation in the magnitudes of the correlations between speech features in the different languages, but the directions of the associations were generally consistent across the four languages in the study. In all four languages, significant correlations with the MMSE were found with both the composite score (‐0.46 ≤ r ≤ ‐0.26) and the object content score (0.27 ≤ r ≤ 0.42).

Conclusion:

Together, these results indicate that there are consistent interrelationships among different speech features across languages. In addition, in the four languages examined, the speech composite score and the number of objects correctly described related to a standard measure of cognition, the MMSE. These results suggest that digital measures of speech and language in MCI/AD are generalizable across languages and relate to cognitive ability more generally. In addition, a composite score of multiple speech features may be more sensitive to cognitive impairment than individual speech metrics.

2025-12-01·Alzheimers & Dementia

The VIVA‐MIND study: Topline Results from Phase 2 RCT of Varoglutamstat in Early AD

Article

作者: Messer, Karen ; Lama, Nicola ; Revta, Carolyn ; Weber, Frank ; Balasubramanian, Archana ; Pol, Alessandra ; Edland, Steven D ; Wenzkowski, Christine ; Jacobs, Diane M. ; Wassmann, Tanja ; Meyer, Antje ; Duehring, Jasmin ; Schell‐Mader, Sylvia ; Leger, Gabriel C ; Schaeffer, Michael ; Zhang, Jing ; Lupo, Jody‐Lynn ; Feldman, Howard H. ; MacKelfresh, Andrew ; Quach, Natalie E

Abstract:

Background:

Varoglutamstat (PQ912) is an oral small molecule inhibitor of glutaminyl cyclases which reduces the pyroglutamate formation of Aβ and CCL2. Preclinical and Ph1 trials support this Ph2 evaluation in early AD. Our objectives included selecting the highest safe and well‐tolerated dose of varoglutamstat with futility analysis at 24 weeks (Ph2A) followed by seamless evaluation of longer‐term safety and efficacy at 72 weeks at this dose (Ph2B).

Method:

Participants with biomarker confirmed early AD were randomized to varoglutamstat or placebo. A sequential design tested 3 descending doses (600mg, 300mg, 150mg BID) using a continuous Pocock safety boundary. A Stage Gate futility analysis of the first 180 subjects at 24 weeks was designed to guide the decision from Ph2A‐B (Figure 1). The Ph2B primary endpoint was CDR‐sum‐of‐boxes (CDR‐SB), with secondary endpoints CFC2, ABC score, spectral EEG, FAQ, ADAS‐Cog‐13, and NPI.

Result:

Table 1 presents baseline characteristics of the 109 randomized and dosed participants. The first dose cohort of varoglutamstat 600mg or placebo did not cross the safety boundary in Ph2A, supporting this dose selection for all participants thereafter. An abbreviated futility analysis was conducted after the trial was terminated prematurely for administrative reasons, with the provisional result of ‘halt enrollment’(yellow) (Figure 1). There were 74% of participants who completed week 24 and 31% week 72 (Figure 2). There were no significant differences between varoglutamstat and placebo in LS mean squares from baseline to week 72 in CDR‐SB (‐0.05 [95% CI ‐1.03, 0.92]), CFC2 (0.97 [95% CI ‐3.34, 5.28]), ABC score (0.10 [95% CI ‐0.10, 0.30]), FAQ (‐0.60 [95% CI ‐4.22, 3.01]), ADAS‐Cog‐13 (2.03 [95% CI ‐2.29, 6.36]); or NPI (‐3.09 [95% CI ‐7.81, 1.62]). At least one TEAE during treatment was reported in 84.9% varoglutamstat and 76.8% placebo with treatment discontinuations due to AE 11.3% varoglutamstat and 3.4% placebo. Severe TEAEs occurred with similar frequencies across arms. Frequency of SAEs/AESIs was 18.9/1.9% varoglutamstat versus 8.9%/5.4% placebo.

Conclusion:

Varoglutamstat was safe and well‐tolerated in this VIVA‐MIND early AD RCT. Efficacy assessment did not demonstrate any significant treatment benefits however, the available sample was limited. Biomarker results and PK/PD are pending.

111

项与 Varoglutamstat 相关的新闻（医药）

2026-09-29

·BioSpace

Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting

Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting Halle (Saale) / Munich, Germany, September 29 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, held its Annual General Meeting (AGM) today at 11:00 a.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appointment of Marcus Irsfeld, CFO of Vivoryon since December 2025, as well as the re-appointment of Dr. Frank Weber and Dr. Michael Schaeffer as executive directors to the Company’s Board. All documents relating to the AGM, including presentation and voting results, are available on the Company’s website: ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Email: IR@vivoryon.com LifeSci Advisors Sandya von der Weid Tel: +41 78 680 05 38 Email: svonderweid@lifesciadvisors.com Attachment 2026-09-29_AGM 2026

高管变更

2026-09-04

·智演生合

【技术分享】递进式扩散模型体系：面向靶标结构与功能机制的先导化合物智能优化

一、背景介绍先导化合物优化是药物研发衔接早期筛选与临床候选开发的核心环节，高度依赖结构解析、化学经验与反复实验验证。当前主流智能配体生成模型多基于分子二维特征与已知配体数据训练，无法充分利用靶标口袋三维几何结构、局部化学环境及关键药效残基信息，导致生成分子仅具备基础化学合理性，难以精准适配靶标空间结构、实现高特异性结合，无法兼顾结合亲和力与药物作用机制，严重限制了AI药物设计的实际落地效果。针对该技术瓶颈，中山大学雷金平副教授联合杨跃东、王桢教授团队，以去噪概率扩散模型为统一技术底座，构建DiffDec、Diffleop、DiffDeCIG递进式分子设计优化体系（图1）。三套模型逐层迭代升级，分别实现靶标三维结构感知适配、化学键约束与亲和力优化、保守残基机制导向设计，形成从结构匹配、性能优化到机制精准调控的完整技术链路，为先导化合物智能化优化提供了全新解决方案。二、实验方法和材料 1.DiffDec三维口袋结构感知骨架修饰模型构建该模型聚焦解决分子与靶标口袋结构适配问题，依托E(3)等变图神经网络，构建三维空间鲁棒的扩散生成架构。模型以蛋白口袋与分子固定骨架为约束，对R基团原子信息进行加噪与反向去噪恢复，精准学习口袋结构与配体构象的匹配规律。创新设计虚拟原子机制，实现不同尺寸R基团的端到端生成，支持单点、多点精准锚定修饰，将传统二维片段拼接升级为三维靶标环境约束下的分子优化，大幅提升分子结构适配性。图2 靶标结构感知的DiffDec 模型框架 2.Diffleop化学键约束与亲和力优化模型搭建在结构适配基础上，模型新增化学键全局扩散与亲和力梯度双引导机制。通过虚拟键设计实现原子坐标、原子类型、化学键的同步扩散学习，保障分子成键合理性；搭建E(3)等变亲和力预测网络，在采样过程中动态计算结合亲和力梯度，引导分子向高结合活性方向迭代优化，同步实现分子结构合规性与结合能力的双重提升。图3 亲和力驱动的Diffleop模型框架 3.DiffDeCIG保守位点机制导向生成模型研发为实现机制精准化设计，模型融入靶标氨基酸保守评分与蛋白-配体相互作用先验知识。通过多序列比对量化残基保守性并编码为口袋特征，结合IPNet预训练网络学习关键作用模式，在扩散生成中调控R基团生长方向，引导分子优先与高保守功能残基形成氢键、疏水作用等特异性结合，实现从亲和力优化到靶向机制精准设计的升级。图4. 保守位点与相互作用引导的DiffDeCIG模型框架三、实验结果分析 1. DiffDec显著提升三维分子修饰精度基准测试结果显示，DiffDec单位点、多位点R基团恢复率分别达69.67%、45.34%，性能全面优于LibINVENT、Pocket2Mol等主流模型。该模型生成的分子可精准贴合靶标口袋空间，蛋白-配体相互作用更稳定，键角、二面角等构象参数贴合天然分子特征，为后续分子性能优化筑牢结构基础。 2. Diffleop可高效优化分子成药性与结合活性多模型对比实验证实，Diffleop在结合亲和力、配体效率等核心指标上优势显著，消融实验验证了化学键约束与亲和力引导的协同增益。团队联合湿实验研究发现，该模型优化的帕金森病sQC抑制剂最优候选物活性提升226倍，药效远超临床在研药物PQ912，具备极高应用价值。 3. DiffDeCIG实现高选择性机制导向药物设计实验表明，DiffDeCIG可有效引导分子靶向高保守功能残基结合，大幅提升药物特异性。依托该模型优化的金黄色葡萄球菌MetRS抑制剂MRS-9，活性较母体提升超300倍，兼具高选择性与三位点独特结合模式，为抗感染药物精准研发提供了新路径。四、讨论和展望本研究构建的递进式扩散模型体系，完成了从三维结构适配、亲和力优化到功能机制导向的全方位技术升级，突破了传统AI药物设计仅拟合分子分布、缺乏生物学约束的局限，建立了多层知识驱动的智能优化新范式。系列模型经干湿实验双重验证，可高效产出高活性、高选择性、高成药性的先导化合物，在神经疾病、抗感染疾病药物研发中展现出极强的落地能力。该递进式技术框架具备良好的拓展性，未来可适配更多疾病靶点与药物类型，进一步融合多组学生物先验知识，优化模型生成精度与特异性，为高通量先导化合物优化、精准靶向药物研发提供高效可靠的智能化技术支撑。智演生合（广州）生物科技有限公司智演生合是一家聚焦蛋白质定向进化与开发的科技平台公司，以SMALT与AI为核心引擎，面向纳米抗体、工业酶及相关功能蛋白的发现、优化和应用开发，构建了集体内进化、高通量筛选、智能预测与实验验证于一体的研发体系。公司致力于把传统依赖经验、周期较长、试错成本高的蛋白研发模式，升级为数据驱动、快速迭代、面向应用场景的高效开发模式。围绕生命健康、工业制造、环境治理等方向，智演生合可为科研机构、生物技术企业和产业客户提供从候选分子获得到性能优化、应用验证的系统化解决方案，帮助客户更快获得可验证、可转化、可持续优化的蛋白产品原型与项目成果。智演生合|提供蛋白发现、优化与应用开发一体化解决方案长按识别二维码，关注智演生合

2026-08-18

·BioSpace

Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026

Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that its 2026 Annual General Meeting will be held on Tuesday, September 29, 2026, at 11:00 a.m. (CEST) at the Amsterdam offices of NautaDutilh N.V. The full agenda and all relevant documents are available on the Company's website: . ### About Vivoryon Therapeutics N.V. Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. Vivoryon Forward Looking Statements This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company’s results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law. For more information, please contact: Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication Email: IR@vivoryon.com LifeSci Advisors Sandya von der Weid Tel: +41 78 680 05 38 Email: svonderweid@lifesciadvisors.com Attachment 2026-08-17_AGM invitation PR

100 项与 Varoglutamstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
轻度痴呆	临床2期	中国	江苏先声药业有限公司	2022-04-26
轻度痴呆	临床2期	中国	Haupt Pharma Wülfing GmbH	2022-04-26
轻度痴呆	临床2期	中国	Vivoryon Therapeutics NV	2022-04-26
轻度认知障碍	临床2期	丹麦	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	丹麦	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	德国	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	德国	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	荷兰	Vivoryon Therapeutics NV	2020-07-06
轻度认知障碍	临床2期	荷兰	Nordic Bioscience A/S	2020-07-06
轻度认知障碍	临床2期	波兰	Nordic Bioscience A/S	2020-07-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03919162 (VIVA-MIND, CTgov)	临床2期	阿尔茨海默症	112	PQ912 (PQ912)	壓鑰窪鏇鏇襯憲餘獵網 = 淵鏇餘積餘選憲膚餘窪繭獵鹹築積獵齋壓繭糧 (艱廠淵願夢選艱淵糧鹽, 遞積齋製鑰艱範構淵顧 ~ 憲襯遞顧壓顧鬱築蓋鑰) 更多	-	2025-12-12
				Placebo (Placebo)	壓鑰窪鏇鏇襯憲餘獵網 = 積網壓鬱艱網繭夢觸選繭獵鹹築積獵齋壓繭糧 (艱廠淵願夢選艱淵糧鹽, 齋觸膚齋淵廠膚構鑰醖 ~ 鑰廠憲獵獵艱鑰獵憲製) 更多
NCT03919162 (VIVA-MIND, GlobeNewswire) 人工标引	临床2期	阿尔茨海默症	-	Varoglutamstat	膚網鏇餘願膚憲鹽廠憲(窪網觸願遞廠鏇餘憲壓) = no clinically meaningful and no statistically significant differences between varoglutamstat 600mg BID and placebo 淵窪夢夢獵襯網顧網鹹 (鬱構築夢艱製艱醖糧選 ) 更多	积极	2024-12-09
				placebo
NCT04498650 (VIVIAD, ASN2024)	临床2期	阿尔茨海默症 \| 轻度认知障碍	259	Varoglutamstat 300 mg	繭選憲願網襯繭繭蓋網(夢餘艱選顧鹽獵窪壓繭) = 觸蓋顧齋壓鹹鬱範餘築繭簾獵襯鹽鏇積衊鑰衊 (糧觸鹹廠鑰遞餘衊夢糧 )	积极	2024-10-25
				Varoglutamstat 600 mg	蓋製鹹顧積積蓋窪網餘(廠積願襯鏇衊憲築蓋鏇) = 艱構繭顧糧窪廠鏇顧壓繭顧窪鏇鹹襯醖醖築網 (築願憲窪獵鬱淵繭襯築 ) 更多
NCT04498650 (VIVIAD, GlobeNewswire \| ASN2024)	临床2期	阿尔茨海默症 \| 糖尿病肾病	32	Varoglutamstat	顧窪網顧醖窪襯夢觸築(艱願網壓鏇顧窪夢繭蓋) = 鏇艱繭襯襯範膚觸夢鏇觸鏇襯鑰築繭鏇鬱構簾 (鑰繭醖糧鹽製簾獵窪蓋 )	积极	2024-10-25
				placebo	顧窪網顧醖窪襯夢觸築(艱願網壓鏇顧窪夢繭蓋) = 憲獵積範顧艱餘壓衊鬱觸鏇襯鑰築繭鏇鬱構簾 (鑰繭醖糧鹽製簾獵窪蓋 )
NCT04498650 (VIVIAD, GlobeNewswire) 人工标引	临床2期	肾脏疾病 CCL2 Expression	-	Varoglutamstat 600mg BID	鏇範衊窪繭齋憲蓋觸艱(鏇鏇醖遞遞鏇艱壓觸壓) = 鑰餘艱構壓獵鏇鬱鬱繭餘壓鏇獵廠廠夢餘鏇壓 (選鬱製衊夢構築糧遞蓋 ) 更多	积极	2024-09-12
NCT04498650 (VIVIAD, Corporate Publications) 人工标引	临床2期	阿尔茨海默症	250	Varoglutamstat	膚鑰築艱鹽鹽蓋襯遞淵(廠製製窪夢鑰遞範鑰鏇) = 觸襯構鏇齋膚淵餘衊範鏇壓醖遞淵獵襯醖鹹壓 (繭憲廠簾鹹製網觸積繭 ) 更多	积极	2022-07-31
NCT02389413 (Pubmed \| Alzheimers Res Ther) 人工标引	临床2期	阿尔茨海默症	120	PQ912	獵網窪網憲淵簾鬱鏇簾(醖襯網淵夢鹽簾簾觸獵) = There was no significant difference between treatments in the number of subjects with (serious) adverse events, although there were slightly more patients with a serious adverse event in the PQ912 group compared to placebo. 選構壓廠鏇廠範鹹壓憲 (鹹鹽壓襯觸壓觸顧糧簾 ) 更多	积极	2018-10-12
				Placebo